BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Meet the Stars of the Feline World: Well known Pet Feline Varieties - 2Dominating Capable Mastercard Utilization: Key Contemplations
- 3These four astronauts could soon travel farther from Earth than anyone has gone before
- 4Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 5Triumph's 400 Range Has Just Changed In India, And Here's Why
- Some Americans say they'll go without health insurance as ACA rates spike
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- Sixteen Kenyans missing in Russia after army recruitment
- German hauliers warn soaring energy prices may soon impact consumers
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- Tens of thousands protest as far-right AfD forms new youth group
- German finance minister sees advantages of smartphones in schools
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- Becoming the best at Discussion: Individual Procedures
